https://european-biotechnology.com/latest-news/novo-nordisks-semaglutide-fails-in-alzheimers/
Novo Nordisk's semaglutide fails in Alzheimer’s - European Biotechnology Magazine
Dec 5, 2025 - Novo Nordisk’s semaglutide has failed to reduce the cognition deficit in two Phase III Alzheimer’s trials, dimming GLP-1 hopes. Anti-amyloid and...
novo nordisksemaglutide fails
https://www.naturalnews.com/2025-12-03-semaglutide-alzheimers-pharma-wonder-drug.html
Semaglutide fails to slow Alzheimer’s in major trials, dealing a blow to pharma’s...
semaglutide failsmajor trials
https://www.psypost.org/semaglutide-improves-biomarkers-but-fails-to-preserve-memory-in-alzheimers-patients/
Semaglutide improves biomarkers but fails to preserve memory in Alzheimer’s patients
Nov 24, 2025 - The popular metabolic drug semaglutide failed to preserve memory in patients with early Alzheimer’s disease. New data shows the treatment did not slow...
preserve memorysemaglutide